Answers are grounded in this paper and cite their sources.
The administration of neurotrophic factors is a potential approach to the therapy of neurodegenerative disorders such as Parkinson's disease. However, issues relating to compound delivery and potential side effects have limited the clinical application of this treatment strategy. The identification of CDNF and MANF, which constitute a new class of neurotrophic factors active against dopaminergic neurons, may provide new hope for therapeutic approaches to neurodegenerative disorders based on neurotrophic factors or downstream components of their signaling pathways.
No takes yet. Share an insight, caveat, or question.
William T. Dauer (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: